Human Dendritic Cell-Derived Induced Pluripotent Stem Cell Lines Are Not Immunogenic

Area of Science:

• Immunology
• Stem Cell Biology
• Regenerative Medicine

Background:

• Donor-specific induced pluripotent stem cells (iPSC) offer potential for cell-replacement therapies.
• Understanding the immunogenicity of human iPSC and their derivatives is crucial for therapeutic safety.
• Previous studies in mouse models suggested potential immunogenicity of syngenic iPSC lines.

Purpose of the Study:

• To characterize the innate and adaptive immune mechanisms of human iPSC derived from dendritic cells.
• To assess the immunogenic potential of these iPSC lines and their derivatives.
• To investigate the mechanisms underlying the immune evasion properties of human iPSC.

Main Methods:

• Generation of human iPSC lines from peripheral blood-derived dendritic cells using Sendai virus.
• Analysis of Toll-like receptor (TLR) and antigen (Ag)-presentation pathway gene expression.
• Assessment of TLR-mediated cytokine responses and inflammasome activation.
• Evaluation of T cell activation in allogeneic mixed lymphocyte reactions (MLR).
• Characterization of MHC class I expression and peptide-binding capabilities.
• Differentiation of iPSC into hematopoietic stem cell precursors and antigen-presenting cells (APC).

Main Results:

• Human iPSC lines express TLR and Ag-presentation pathway mRNA, but not functional proteins.
• These iPSC lines do not induce TLR-mediated inflammatory cytokine responses or inflammasome activation.
• iPSC lines do not activate T cells in MLR, but express low MHC class I levels capable of peptide acquisition.
• Efficient differentiation into hematopoietic stem cell precursors and APC is achievable.
• Dedifferentiation of dendritic cells into iPSC effectively suppresses immunogenic pathways.

Conclusions:

• Human iPSC derived from dendritic cells exhibit significantly reduced immunogenicity.
• Transcriptional and posttranscriptional mechanisms contribute to the suppression of immune pathways in iPSC.
• These findings support the development of safer cell-replacement therapies using iPSC-derived cells.